GPC3-CAR-Super IL2

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameGPC3-CAR-Super IL2
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapy > Chimeric antigen receptor Macrophages therapy > in vivo CAR-Macrophages therapyCell and gene therapy > Cell therapy > In vivo cell therapy > in vivo CAR-Macrophages therapy
Mechanisms of ActionGlypican-3 inhibitors
TargetsGlypican-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A